{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:28:49Z","timestamp":1784204929257,"version":"3.55.0"},"reference-count":23,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T00:00:00Z","timestamp":1698537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Purpose: Enterococcal bacteremia is associated with high mortality and long-term hospitalization. Here, we aimed to investigate the clinical outcomes and evaluate the risk factors for mortality in adult patients treated with vancomycin (VCM) for vancomycin-susceptible Enterococcus faecium (E. faecium) bacteremia. Methods: This is a retrospective, record-based study. The data were collected from inpatients at a single university hospital between January 2009 and December 2020. The area under the curve (AUC) of VCM was calculated using the Bayesian approach. The primary outcome was a 30-day in-hospital mortality. Results: A univariate analysis showed significant differences in the concomitant use of vasopressors, history of the use of no clinically relevant activity antimicrobial agents against E. faecium, VCM plasma trough concentration, and renal dysfunction during VCM administration between the 30-day in-hospital mortality and survival groups. However, the groups\u2019 AUC\/minimum inhibitory concentration (MIC) were not significantly different. A multivariate analysis suggested that concomitant vasopressors may be an independent risk factor for 30-day in-hospital mortality (odds ratio, 7.81; 95% confidence interval, 1.16\u201352.9; p = 0.035). The VCM plasma trough concentrations and the AUC\/MIC in the mortality group were higher than those in the surviving group. No association between the AUC\/MIC and the treatment effect in E. faecium bacteremia was assumed, because the known, target AUC\/MIC were sufficiently achieved in the mortality group. Conclusions: There may be no association between the AUC\/MIC and the treatment effect in E. faecium bacteremia. When an immunocompromised host develops E. faecium bacteremia with septic shock, especially when a vasopressor is used in a patient with unstable hemodynamics, it may be difficult to treat it, despite efforts to ensure the appropriate AUC\/MIC and therapeutic vancomycin concentration levels.<\/jats:p>","DOI":"10.3390\/antibiotics12111577","type":"journal-article","created":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T05:01:08Z","timestamp":1698555668000},"page":"1577","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Assessing Clinical Outcomes of Vancomycin Treatment in Adult Patients with Vancomycin-Susceptible Enterococcus faecium Bacteremia"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4450-0280","authenticated-orcid":false,"given":"Hiroshi","family":"Sasano","sequence":"first","affiliation":[{"name":"Department of Pharmacometrics and Pharmacokinetics, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan"},{"name":"Department of Pharmacy, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo 136-0075, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9041-5589","authenticated-orcid":false,"given":"Kazuhiko","family":"Hanada","sequence":"additional","affiliation":[{"name":"Department of Pharmacometrics and Pharmacokinetics, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4103\/0974-777X.93758","article-title":"Enterococcal bacteremia is associated with prolonged stay in the medical intensive care unit","volume":"4","author":"Moses","year":"2012","journal-title":"J. Glob. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1086\/318717","article-title":"Attributable mortality rate and duration of hospital stay associated with enterococcal bacteremia","volume":"32","author":"Becerril","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1017\/ice.2016.254","article-title":"Incidence and outcomes associated with infections caused by vancomycin-resistant enterococci in the United States: Systematic literature review and meta-analysis","volume":"38","author":"Chiang","year":"2017","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/nrmicro2761","article-title":"The rise of the Enterococcus: Beyond vancomycin resistance","volume":"10","author":"Arias","year":"2012","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s12275-014-4011-6","article-title":"Enterococcus infection biology: Lessons from invertebrate host models","volume":"52","author":"Yuen","year":"2014","journal-title":"J. Microbiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health System Pharmacists","volume":"71","author":"Rybak","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e01602","DOI":"10.1128\/AAC.01602-17","article-title":"Pharmacokinetic\/pharmacodynamic determinants of vancomycin efficacy in enterococcal bacteremia","volume":"62","author":"Jumah","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin. Pract."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Gudiol, C., Ayats, J., Camoez, M., Dom\u00ednguez, M.\u00c1., Vidal, C.G., Bodro, M., Ardanuy, C., Obed, M., Arnan, M., and Antonio, M. (2013). Increase in bloodstream infection due to vancomycin-susceptible Enterococcus faecium In cancer patients: Risk factors, molecular epidemiology and outcomes. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0074734"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijid.2014.02.012","article-title":"Incidence, risk factors, and outcomes for Enterococcus spp. blood stream infections: A population-based study","volume":"26","author":"Billington","year":"2014","journal-title":"Int. J. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ccc.2007.12.012","article-title":"Vancomycin revisited: A reappraisal of clinical use","volume":"24","author":"Cunha","year":"2008","journal-title":"Crit. Care Clin."},{"key":"ref_12","unstructured":"Jameson, J. (2018). Harrison\u2019s Principles of Internal Medicine, McGraw-Hill. [20th ed.]."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S1119","DOI":"10.21037\/jtd.2018.04.14","article-title":"Does immunosuppression affect the course of septic shock?","volume":"10","author":"Aygencel","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/CCM.0000000000002255","article-title":"Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016","volume":"45","author":"Rhodes","year":"2017","journal-title":"Crit. Care Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Miyai, T., Imai, S., Kashiwagi, H., Sato, Y., Kadomura, S., Yoshida, K., Yoshimura, E., Toshiaki, T., Takashi, T., and Kawamoto, Y. (2020). A risk prediction flowchart of vancomycin-induced acute kidney injury to use when starting vancomycin administration: A multicenter retrospective study. Antibiotics, 9.","DOI":"10.3390\/antibiotics9120920"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Uda, A., Shigemura, K., Kitagawa, K., Osawa, K., Onuma, K., Yonmin, Y., Nishioka, T., Fujisawa, M., Yano, I., and Miyara, T. (2021). Risk factors for the acquisition of Enterococcus faecium infection and mortality in patients with enterococcal bacteremia: A 5-year retrospective analysis in a tertiary care university hospital. Antibiotics, 10.","DOI":"10.3390\/antibiotics10010064"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/jgs.15391","article-title":"Predictors of mortality with Staphylococcus aureus bacteremia in elderly adults","volume":"66","author":"Bassetti","year":"2018","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Bassetti, M., Peghin, M., Trecarichi, E.M., Carnelutti, A., Righi, E., Giacomo, P.D., Ansaldi, F., Trucchi, C., Alicino, C., and Cauda, R. (2017). Characteristics of Staphylococcus aureus bacteraemia and predictors of early and late mortality. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0170236"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s15010-018-1151-3","article-title":"Prognostic factors and scoring model of hematological malignancies patients with bloodstream infections","volume":"46","author":"Tang","year":"2018","journal-title":"Infection"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1186\/cc7713","article-title":"Characteristics and outcomes of cancer patients in European ICUs","volume":"13","author":"Taccone","year":"2009","journal-title":"Crit. Care"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1097\/CCM.0000000000002722","article-title":"Time course of septic shock in Immunocompromised and Nonimmunocompromised patients","volume":"45","author":"Jamme","year":"2017","journal-title":"Crit. Care Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jiac.2020.05.012","article-title":"Concomitant vancomycin and piperacillin\/tazobactam treatment is associated with an increased risk of acute kidney injury in Japanese patients","volume":"26","author":"Haruki","year":"2020","journal-title":"J. Infect. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.ijantimicag.2018.08.001","article-title":"Comparative incidence and excess risk of acute kidney injury in hospitalised patients receiving vancomycin and piperacillin\/tazobactam in combination or as monotherapy","volume":"52","author":"Carreno","year":"2018","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/11\/1577\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:13:40Z","timestamp":1760130820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/11\/1577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,29]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["antibiotics12111577"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12111577","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,29]]}}}